Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
AbbVie (2)
54 Articles Available
2
3
Can't find what you're looking for? Try our
advanced search
.
Pancreatic Cancer
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer
PR-M01-19-NI-061
Leadership
AbbVie Announces Executive Leadership Changes
PR-M01-19-NI-003
Drug Development
AbbVie Exercises Option to License Parkinson’s Tech from BioArctic
PAO-M12-18-NI-015
Oncology
IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR
PR-M12-18-NI-017
Licensing Agreement
Pfizer to License AbbVie’s Humira IP
PAO-M12-18-NI-006
Drug Development
AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
PR-M11-18-NI-053
Investment
US Tax Savings Help AbbVie
PAO-M11-18-NI-012
Financial Results
AbbVie Reports Third-Quarter 2018 Financial Results
PR-M11-18-NI-012
Patent
Humira Patent Disputes between Novartis and Abbvie Settled
PAO-M10-18-NI-021
Phase 3
AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting
PR-M10-18-NI-041
Donation
AbbVie Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families
PR-M09-18-NI-088
FDA Approval
AbbVie Receives FDA Approval for IMBRUVICA® Plus Rituximab as a Blood Cancer Treatment
PAO-M08-18-NI-027
FDA Approval
AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
PR-M07-18-NI-078
New Drug Application
AbbVie Announces Submission of Supplemental New Drug Application to US FDA for Venetoclax
PR-M07-18-NI-041
Strategic Collaboration
AbbVie and Calico Announce Extension of Groundbreaking Collaboration
PR-M06-18-NI-092
Trial Results
IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
PR-M05-18-NI-102
Authorization Application
AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
PR-M05-18-NI-016
Clinical Data
AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
PR-M05-18-NI-008
FDA
AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
PR-M04-18-NI-103
Clinical Trials
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
PR-M04-18-NI-102
Clinical Trials
AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T)
PR-M03-18-NI-088
Clinical Trials
AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
PR-M03-18-NI-057
Oncology
AbbVie Receives Positive Recommendation from the Pan-Canadian Oncology Drug Review for VENCLEXTA™
PR-M03-18-NI-030
Strategic Collaboration
AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Neurodegenerative Diseases
PR-M02-18-NI-82
«
2
3
»
.svg)